In recent years, the detection of BRCA1 or 2 mutations in patients with breast cancer (BC) or ovarian cancer (OC) has become crucial to tailor their treatment, for instance through more extensive surgery and/or anti-neoplastic drugs that have proven to be specifically effective in BRCA mutation carriers, such as PARP-inhibitors [1]. Here, BRCA1 is linked to breast cancer.